Opus Genetics, Inc. (FRA:R3X1)

Germany · Delayed Price · Currency is EUR

1.886

+0.120 (6.80%)

At close: Dec 4, 2025

68.09% (1Y)

Market Cap	131.88M
Revenue (ttm)	12.47M
Net Income (ttm)	-58.13M
Shares Out	n/a
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	334
Open	1.760
Previous Close	1.766
Day's Range	1.760 - 1.902
52-Week Range	0.575 - 2.005
Beta	n/a
RSI	63.65
Earnings Date	Mar 30, 2026

About Opus Genetics

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutation... [Read more]

Industry Pharmaceutical Preparations

Founded 2018

Employees 18

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol R3X1

Full Company Profile

Financial Performance

In 2024, Opus Genetics's revenue was $10.99 million, a decrease of -42.30% compared to the previous year's $19.05 million. Losses were -$57.53 million, 476.1% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.